Iron catalysed, site-selective functionalisation reactions: Cutting edge analysis for state-of-the-art synthesis

点击翻译按钮获取中文摘要

Chiral hydrofluorinated molecules are important active pharmaceutical ingredients, crucial for 19F radiolabelling and application in medical imaging such as Positron Emission Tomography (PET). Achieving hydrofluorination and installing charity on unactivated alkenes remains a challenge to chemists.AimTo achieve enantioselective hydrofluorination of unactivated alkenesOBJECTIVESDevelop a regioselective hydrofluorination of unactivated alkenesRegioselective preparation of value-added fluorinated moleculesDevelop chiral-by-virtue of deuterium-substituted compoundsMass spectrometry method development to characterise, monitor and quantify the reactionsPotential application of researchApplication in the synthesis of drug motifApplication in medical imagingApplication in radiolabelling with Fluorine-19Benefit of research Expanding the scope available to chemists to access regioselective and enantioselective fluorination and deuterationDeveloping analytical methods with mass spectrometry to monitor and quantify enantioselective reactionsRelevance to goals of the fundersThis project aligns with the priorities of EPSRC of developing human capital in the physical sciences in the UK to benefit society and, mankind through scientific innovation.This project aligns with the business priorities of GSK of continuous innovation in drug design and delivery.Role of the second supervisor (Dr Kathryn Proctor)Dr Kathryn Proctor is an expert mass spectrometrist at MC2. She will oversee and supervise the analysis of the racemate and regioselective fluorinated compounds using mass spectrometry. A wide range of activities not limited to method development, one-on-one training on instrumentation, data analysis, and reaction condition screening are some of the technical contributions she will make to this project as a co-supervisor.